Caterina cu Lapenta

List of Publications by Year
in descending order

38	2,210	304368	360668
papers	citations	22 h-index	35 g-index

40	40	40	2576
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19. Cytokine and Growth Factor Reviews, 2021, 58, 66-74.	3.2	14
2	IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. Vaccines, 2020, 8, 617.	2.1	14
3	Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma. Cancer Immunology, Immunotherapy, 2020, 69, 913-925.	2.0	7
4	INTRANODAL TREATMENT WITH IFNÎ‘-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematological Oncology, 2019, 37, 317-318.	0.8	0
5	Lenalidomide improves the therapeutic effect of an interferon-Î±-dendritic cell-based lymphoma vaccine. Cancer Immunology, Immunotherapy, 2019, 68, 1791-1804.	2.0	18
6	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNÎ±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	3.2	34
7	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	0.6	0
8	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1356964.	2.1	42
9	NK Cell Activation in the Antitumor Response Induced by IFN-Î± Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. Journal of Immunology, 2016, 197, 795-806.	0.4	19
10	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. Blood, 2016, 128, 2976-2976.	0.6	5
11	Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. International Journal of Cancer, 2015, 137, 1491-1497.	2.3	34
12	IFN-Î± enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood, 2012, 119, 1407-1417.	0.6	119
13	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine, 2011, 29, 3465-3475.	1.7	17
14	Interferon-Î±-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12. PLoS ONE, 2011, 6, e17364.	1.1	60
15	Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology, 2009, 395, 45-55.	1.1	39
16	Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clinical and Experimental Immunology, 2009, 155, 28-34.	1.1	53
17	In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. European Journal of Cancer, 2009, 45, 2606-2617.	1.3	30
18	IFN-alpha in the Generation of Dendritic Cells for Cancer Immunotherapy. Handbook of Experimental Pharmacology, 2009, , 295-317.	0.9	53

#	Article	IF	Citations
19	Differentiation of monocyte-derived dendritic cells is associated with upregulation and activation of Rac-1 small GTPase. FEBS Letters, 2006, 580, 3335-3339.	1.3	4
20	IFN-Î±-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. European Journal of Immunology, 2006, 36, 2046-2060.	1.6	132
21	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. International Immunology, 2005, 17, 469-475.	1.8	22
22	Type I Interferons as Regulators of the Differentiation/Activation of Human Dendritic Cells. , 2005, 116, 167-181.		12
23	CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. European Journal of Immunology, 2003, 33, 358-367.	1.6	26
24	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-Î±. Journal of Experimental Medicine, 2003, 198, 361-367.	4.2	130
25	Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8927-8932.	3.3	40
26	The Natural Alliance Between Type I Interferon and Dendritic Cells and Its Role in Linking Innate and Adaptive Immunity. Journal of Interferon and Cytokine Research, 2002, 22, 1071-1080.	0.5	77
27	Expression of CCR-7, MIP-3Î², and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood, 2001, 98, 3022-3029.	0.6	231
28	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. Aids, 2001, 15, 2231-2238.	1.0	41
29	Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of chronically infected cells through a massive Fas-mediated autocrine suicide of uninfected cells. Cell Death and Differentiation, 2000, 7, 37-47.	5.0	12
30	Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice. Journal of Experimental Medicine, 2000, 191, 1777-1788.	4.2	590
31	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4+ T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. Virology, 1999, 263, 78-88.	1.1	57
32	Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. European Journal of Immunology, 1999, 29, 1202-1208.	1.6	120
33	Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. Journal of Virology, 1999, 73, 6453-6459.	1.5	43
34	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. Transplantation, 1998, 65, 416-420.	0.5	17
35	Human Lymphoblastoid CD4 ⁺ T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 ⁺ T-Cell Differentiation in Pathogenesis of AIDS. Journal of Virology, 1998, 72, 10323-10327.	1.5	12
36	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Research, 1997, 36, 81-90.	1.9	19

#	Article	IF	Citations
37	T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. Journal of Virology, 1996, 70, 7958-7964.	1.5	49
38	THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT. Transplantation, 1995, 60, 1306-1313.	0.5	18